

INOmax[®]
(nitric oxide) FOR INHALATION

Ikaria[®] Event Invitation

You are cordially invited to attend an informational presentation titled "**Case Study: Inhaled Nitric Oxide for Infants With Hypoxic Respiratory Failure (HRF).**"

Featured Presenter:

Dan Stewart, MD
Professor, Department of Pediatrics, Neonatology
Kosair Children's Hospital

Program Topics:

- Review pathophysiology of neonatal HRF
- Discuss representative case studies, including treatment and the role of inhaled nitric oxide (iNO)
- Evidence for the earlier use of iNO in the treatment of HRF

Friday, February 27 at 8:00 PM

House Of Blues

1055 5th Avenue
San Diego, CA 92101

www.houseofblues.com/sandiego



Map It

Bus transportation will be provided to and from the restaurant. Buses will depart at 7:30 PM outside the Coronado Island Marriott Resort & Spa.

Please RSVP by Thursday, February 26.

If you have any questions, please contact:

Important Safety Information

INOMAX[®] is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

Utilize additional therapies to maximize oxygen delivery with validated ventilation systems.

- INOMAX is contraindicated in the treatment of neonates known to be dependent on right-to-left shunting of blood.
- Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation.
- Methemoglobinemia and NO₂ levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of

Melissa Nichols

Phone: (504) 232-8099

Email: melissa.nichols@ikaria.com

Michelle Walton

Phone: (562) 458-1137

Email: michelle.walton@ikaria.com

Dale Lindgren

Phone: (650) 740-0686

Email: dale.lindgren@ikaria.com

Ward Rolland

Phone: (213) 503-9939

Email: ward.rolland@ikaria.com

Florizel Mason

Phone: (916) 223-2228

Email: florizel.mason@ikaria.com

developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.

- In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.
- Monitor for PaO₂, methemoglobin, and inspired NO₂ during INOMAX administration.
- Use only with an INOmax DS_{IR}[®], INOmax[®] DS, or INOvent[®] operated by trained personnel.

Please see [Full Prescribing Information](#).

To ensure you receive email from INOMAX[®], please [add us to your address book](#).

Ikaria Corporate Headquarters
Perryville III Corporate Park | 53 Frontage Road, Third Floor
PO Box 9001 | Hampton, NJ 08827
1-908-238-6600 | www.INOMAX.com

IMK-222-40001 Template July 2014

© 2014 Ikaria, Inc.

INOMAX[®], INOvent[®], INOcal[®], DS_{IR}[®], and INOMAX Total Care[®] are registered trademarks of INO Therapeutics LLC.